Schonfeld Strategic Advisors’s 89bio ETNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-272,094
| Closed | -$4M | – | 2191 |
|
|
2025
Q3 | $4M | Sell |
272,094
-111,094
| -29% | -$1.13M | 0.02% | 691 |
|
|
2025
Q2 | $3.76M | Buy |
+383,188
| New | +$3.17M | 0.03% | 674 |
|
|
2024
Q3 | – | Sell |
-40,488
| Closed | -$324K | – | 2145 |
|
|
2024
Q2 | $324K | Sell |
40,488
-93,566
| -70% | -$835K | ﹤0.01% | 1654 |
|
|
2024
Q1 | $1.56M | Buy |
134,054
+56,296
| +72% | +$623K | 0.01% | 1070 |
|
|
2023
Q4 | $869K | Sell |
77,758
-199,804
| -72% | -$1.84M | 0.01% | 1079 |
|
|
2023
Q3 | $4.29M | Buy |
277,562
+41,958
| +18% | +$704K | 0.03% | 592 |
|
|
2023
Q2 | $4.46M | Sell |
235,604
-117,642
| -33% | -$2.07M | 0.04% | 520 |
|
|
2023
Q1 | $5.38M | Sell |
353,246
-126,797
| -26% | -$1.65M | 0.05% | 426 |
|
|
2022
Q4 | $6.11M | Buy |
480,043
+130,183
| +37% | +$1.17M | 0.05% | 425 |
|
|
2022
Q3 | $2.02M | Buy |
349,860
+105,886
| +43% | +$465K | 0.02% | 852 |
|
|
2022
Q2 | $787K | Buy |
243,974
+231,774
| +1,900% | +$700K | 0.01% | 1130 |
|
|
2022
Q1 | $46K | Buy |
+12,200
| New | +$78.6K | ﹤0.01% | 2347 |
|
|
2021
Q1 | – | Sell |
-45,500
| Closed | -$1.11M | – | 1880 |
|
|
2020
Q4 | $1.11M | Sell |
45,500
-11,000
| -19% | -$281K | 0.01% | 773 |
|
|
2020
Q3 | $1.45M | Buy |
+56,500
| New | +$1.79M | 0.03% | 601 |
|
|
2020
Q1 | – | Sell |
-26,840
| Closed | -$705K | – | 1244 |
|
|
2019
Q4 | $705K | Buy |
+26,840
| New | +$747K | 0.02% | 616 |
|
Other funds holding ETNB
Schonfeld Strategic Advisors's ETNB Position: Q4 2025 in Review
Schonfeld Strategic Advisors sold out of 89bio (ETNB) in Q4 2025, closing a stake of 272,094 shares — an estimated $4M sold.
Schonfeld Strategic Advisors first reported a position in ETNB in Q4 2019 and held it in 15 quarters. The position peaked at $6.11M in Q4 2022. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.
- Schonfeld Strategic Advisors reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 272,094 89bio shares in Q4 2025, an estimated $4M.
- Schonfeld Strategic Advisors first reported a position in 89bio in Q4 2019 and held it in 15 quarters.
- Schonfeld Strategic Advisors's 89bio position peaked at $6.11M in Q4 2022.
- 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.